Complete Pacer Lunt MidCap Multi-Factor Alternator ETF funds overview by Barron's. View the PAMC funds market news ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...

Disconnected ecommerce and POS systems cost the average multi channel Shopify merchant somewhere between two and five percent ...

GPT-Realtime-2 brings GPT-5-class reasoning to live voice. A separate translation model covers 70+ input languages. A streaming Whisper variant handles transcription. The pricing is aggressive enough ...

OpenAI said Thursday that its API will now include a number of new voice intelligence features designed to help developers create apps that can talk, transcribe, and translate conversations with users ...

OpenAI explains in more detail what’s new with the GPT-5-class GPT-Realtime-2 voice model with reasoning: GPT‑Realtime‑2 is built for live voice interactions where the model keeps the conversation ...

Entrada Therapeutics’ Duchenne muscular dystrophy (DMD) data have fallen well short of expectations, crashing the biotech’s stock as investors evaluated the fallout from a key readout expected to ...

Oracle (ORCL) rallied 24% in the past month to $182.96 on the back of $553 billion in remaining performance obligations (contracted revenue), Q3 revenue of $17.19 billion with 20%+ organic growth, ...

It can be challenging to identify trading ideas that align with your risk profile. To help you through this process, we've ...

Hyperscalers are spending hundreds of billions on data center buildout, creating supply shortages that favor cooling, connectivity, and power infrastructure providers over overvalued computing stock ...

WASHINGTON, April 28 (Reuters) - The U.S. Food and Drug Administration launched a pilot program on Monday aimed at allowing the ‌agency to monitor clinical trial data in real time, a step the agency ...

Erasca has backed up bullish claims about its pan-RAS drug having a best-in-class profile, publishing phase 1 data that an analyst said reveal a “home run profile.” But with a patient dying and ...